<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><?OLF?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Lymphoma Myeloma Leuk</journal-id><journal-id journal-id-type="iso-abbrev">Clin Lymphoma Myeloma Leuk</journal-id><journal-title-group><journal-title>Clinical Lymphoma, Myeloma &#x00026; Leukemia</journal-title></journal-title-group><issn pub-type="ppub">2152-2650</issn><issn pub-type="epub">2152-2669</issn><publisher><publisher-name>The Authors. Published by Elsevier Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7138188</article-id><article-id pub-id-type="publisher-id">S2152-2650(20)30089-6</article-id><article-id pub-id-type="doi">10.1016/j.clml.2020.02.009</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Young</surname><given-names>Patricia A.</given-names></name><email>pyoung@mednet.ucla.edu</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Gaut</surname><given-names>Daria</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Kimaiyo</surname><given-names>Davis K.</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Grotts</surname><given-names>Jonathan</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Romero</surname><given-names>Tahmineh</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au6"><name><surname>Chute</surname><given-names>John</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au7"><name><surname>Schiller</surname><given-names>Gary</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au8"><name><surname>de Vos</surname><given-names>Sven</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au9"><name><surname>Eradat</surname><given-names>Herbert A.</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au10"><name><surname>Timmerman</surname><given-names>John</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA</aff><aff id="aff2"><label>2</label>Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA</aff><aff id="aff3"><label>3</label>Division of General Internal Medicine and Health Services Research, Department of Medicine Statistics Core, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA</aff><author-notes><corresp id="cor1"><label>&#x02217;</label>Address for correspondence: Patricia A. Young, MD, Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, 2020 Santa Monica Blvd, Suite 600, Santa Monica, CA 90404 <email>pyoung@mednet.ucla.edu</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>20</day><month>2</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="epub"><day>20</day><month>2</month><year>2020</year></pub-date><elocation-id/><history><date date-type="received"><day>12</day><month>12</month><year>2019</year></date><date date-type="rev-recd"><day>31</day><month>1</month><year>2020</year></date><date date-type="accepted"><day>9</day><month>2</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 The Authors</copyright-statement><copyright-year>2020</copyright-year><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="abs0010"><sec><title>Background</title><p>High-dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) has been investigated in patients with primary central nervous system lymphoma (PCNSL) and non-Hodgkin lymphoma (NHL) with CNS involvement and has shown promising results.</p></sec><sec><title>Patients and Methods</title><p>A retrospective analysis was performed of 48 consecutive patients who had undergone HDC/ASCT with TBC (thiotepa, busulfan, cyclophosphamide) conditioning for PCNSL (27 patients), secondary CNS lymphoma (SCNSL) (8 patients), or relapsed disease with CNS involvement (13 patients) from July 2006 to December 2017. Of the 27 patients with PCNSL, 21 had undergone ASCT at first complete remission (CR1).</p></sec><sec><title>Results</title><p>The 2-year progression-free survival (PFS) rate was 80.5% (95% confidence interval [CI], 69.9-92.9) and the 2-year overall survival (OS) rate was 80.1% (95% CI, 69.2%-92.7%) among all patients. The 2-year PFS and OS rate for patients with PCNSL in CR1 was 95.2% (95% CI, 86.6%-100%) and 95.2% (95% CI, 86.6%-100%), respectively. On univariate analysis of the patients with PCNSL, ASCT in CR1 was the only variable statistically significant for outcome (<italic>P</italic>&#x000a0;= .007 for PFS; <italic>P</italic>&#x000a0;= .008 for OS). Among patients with SCNSL or CNS relapse, the 2-year PFS and OS rate were comparable at 75.9% (95% CI, 59.5%-96.8%) and 75.3% (95% CI, 58.6%-98.6%), respectively. The most common side effects were febrile neutropenia (89.6%; of which 66.7% had an infectious etiology identified), nausea/vomiting (85.4%), diarrhea (93.8%), mucositis (89.6%), and electrolyte abnormalities (89.6%). Four patients (8.3%) died of treatment-related overwhelming infection; of these patients, 3 had SCNSL.</p></sec><sec><title>Conclusion</title><p>HDC and ASCT using TBC conditioning for both PCNSL and secondary CNS NHL appears to have encouraging long-term efficacy with manageable side effects.</p></sec></abstract><abstract abstract-type="teaser" id="abs0015"><title>Micro-Abstract</title><p>We retrospectively analyzed the data from 48 patients with central nervous system lymphoma who had received high-dose chemotherapy and autologous stem cell transplantation using TBC (thiotepa, busulfan, cyclophosphamide) conditioning. The 2-year progression-free and overall survival rate was 80.5% and 80.1%, respectively. Toxicities included nausea/vomiting, diarrhea, mucositis, and febrile neutropenia. Treatment-related mortality was 8.3% in the first 100 days after transplantation. These data support the use of consolidative autologous stem cell transplantation for patients with primary or secondary central nervous system lymphoma.</p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>ASCT</kwd><kwd>Non-Hodgkin lymphoma</kwd><kwd>PCNSL</kwd><kwd>Relapse</kwd><kwd>SCNL</kwd></kwd-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p id="p0010">Both primary central nervous system (CNS) lymphoma (PCNSL) and non-Hodgkin lymphoma (NHL) with CNS involvement have historically carried poor prognoses.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> However, the increased efficacy of induction chemotherapy and the addition of consolidation therapy have resulted in improvements in recent years.</p><p id="p0015">Although high-dose methotrexate (HD-MTX), alone or combined with other agents, has become the mainstay of induction therapy,<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> the optimal consolidation strategy has not yet been established. Consolidative whole-brain radiation therapy (WBRT) has been used; however, given the low survival benefit and high risk of neurotoxicity with this approach,<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref>
<sup>,</sup>
<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> efforts have ensued to identify alternative options. High-dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) has been investigated for postremission consolidation and for relapsed disease, with promising results.<xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref>
</p><p id="p0020">HD-MTX&#x02013;based induction regimens, followed by ASCT, with various conditioning regimens, including BEAM (carmustine, etoposide, cytarabine, melphalan),<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref>
<sup>,</sup>
<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref>
<sup>,</sup>
<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> thiotepa, busulfan,<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref>
<sup>,</sup>
<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> TBC (thiotepa, busulfan, cyclophosphamide),<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref>
<sup>,</sup>
<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref>
<sup>,</sup>
<xref rid="bib13" ref-type="bibr">13</xref>, <xref rid="bib14" ref-type="bibr">14</xref>, <xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib16" ref-type="bibr">16</xref>, <xref rid="bib17" ref-type="bibr">17</xref>, <xref rid="bib18" ref-type="bibr">18</xref>, <xref rid="bib19" ref-type="bibr">19</xref>, <xref rid="bib20" ref-type="bibr">20</xref> and thiotepa, carmustine<xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib22" ref-type="bibr">22</xref>, <xref rid="bib23" ref-type="bibr">23</xref>, <xref rid="bib24" ref-type="bibr">24</xref>, <xref rid="bib25" ref-type="bibr">25</xref>, <xref rid="bib26" ref-type="bibr">26</xref> have been evaluated. The data thus far, however, have been limited to single-arm phase II trials, and several important questions remain, including the best candidates for such therapy, timing of its use, possible toxicities, and optimal conditioning regimen. We performed a single institution retrospective analysis of consecutive patients with PCNSL, secondary CNS lymphoma (SCNSL), or relapsed CNS lymphoma who had undergone consolidative ASCT with TBC conditioning based on early experiences using this regimen.<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref>
<sup>,</sup>
<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref>
</p></sec><sec id="sec2"><title>Patients and Methods</title><sec id="sec2.1"><title>Patients</title><p id="p0025">From July 2006 to December 2017, the data from all patients with NHL who had undergone ASCT with the TBC conditioning regimen at the University of California, Los Angeles, were retrospectively reviewed. Three groups of patients were included: those with PCNSL, defined as lymphoma confined to the CNS, including intraocular lymphoma; those with SCNSL, defined as lymphoma with systemic disease and CNS involvement; and those with CNS relapse, defined as initial diagnosis of systemic lymphoma, followed by relapse in the CNS, with or without systemic involvement at relapse. The patients with SCNSL and CNS relapse were grouped together as patients with systemic lymphoma with CNS involvement, whether found at the initial diagnosis or on relapse. The primary analysis included PCNSL patients who had undergone ASCT in first complete remission (CR1). Patients with SCNSL or with CNS involvement at relapse were analyzed separately.</p></sec><sec id="sec2.2"><title>Treatment</title><p id="p0030">For patients with PCNSL, a uniform induction therapy was given, consisting of rituximab 375 mg/m<sup>2</sup> and HD-MTX 8 g/m<sup>2</sup>, followed by rituximab 375 mg/m<sup>2</sup>, cytarabine 2&#x000a0;&#x000d7; 3 g/m<sup>2</sup>, and thiotepa 40 mg/m<sup>2</sup>, in accordance with reported data.<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref> The number of cycles of rituximab/HD-MTX and rituximab/cytarabine/thiotepa was determined by physician preference. The dosages were adjusted at the physicians&#x02019; discretion for organ toxicity, tolerance, and/or functional status. For patients with SCNSL or relapsed disease, a variety of chemotherapy regimens were used at the clinician&#x02019;s discretion with a goal of achieving CR before ASCT (<xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>
). Remission status was assessed using magnetic resonance imaging and/or positron emission tomography of the brain before transplantation and, ultimately, interpreted by the treating physician.<table-wrap position="float" id="tbl1"><label>Table&#x000a0;1</label><caption><p>Pretransplantation Therapy Regimens Stratified by Group</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Regimen</th><th>All Patients (n&#x000a0;= 48)</th><th>PCNSL (n&#x000a0;= 27)</th><th>SCNSL/CNS Relapse (n&#x000a0;= 21)</th></tr></thead><tbody><tr><td>R-CHOP</td><td align="char">6 (12.5)</td><td align="char">0 (0)</td><td align="char">6 (28.6)</td></tr><tr><td>R-EPOCH</td><td align="char">9 (18.8)</td><td align="char">0 (0)</td><td align="char">9 (42.9)</td></tr><tr><td>R-DHAP</td><td align="char">6 (12.5)</td><td align="char">0 (0)</td><td align="char">6 (28.6)</td></tr><tr><td>R-DHAOx</td><td align="char">2 (4.2)</td><td align="char">0 (0)</td><td align="char">2 (9.5)</td></tr><tr><td>HyperCVAD</td><td align="char">1 (2.1)</td><td align="char">0 (0)</td><td align="char">1 (4.8)</td></tr><tr><td>CHOEP</td><td align="char">1 (2.1)</td><td align="char">0 (0)</td><td align="char">1 (4.8)</td></tr><tr><td>Temozolomide</td><td align="char">4 (8.3)</td><td align="char">3 (11.1)</td><td align="char">1 (4.8)</td></tr><tr><td>Belinostat</td><td align="char">1 (2.1)</td><td align="char">0 (0)</td><td align="char">1 (4.8)</td></tr><tr><td>Topotecan</td><td align="char">1 (2.1)</td><td align="char">1 (3.7)</td><td align="char">0 (0)</td></tr><tr><td>Rituximab</td><td align="char">44 (91.7)</td><td align="char">26 (96.3)</td><td align="char">18 (85.7)</td></tr><tr><td>HD-MTX</td><td align="char">41 (85.4)</td><td align="char">27 (100)</td><td align="char">14 (66.7)</td></tr><tr><td>HD-Ara-C</td><td align="char">30 (62.5)</td><td align="char">26 (96.3)</td><td align="char">4 (19.0)</td></tr><tr><td>Thiotepa</td><td align="char">25 (52.1)</td><td align="char">25 (92.6)</td><td align="char">0 (0)</td></tr><tr><td>IT-MTX</td><td align="char">8 (16.7)</td><td align="char">0 (0)</td><td align="char">8 (38.1)</td></tr><tr><td>IT-Ara-C</td><td align="char">7 (14.6)</td><td align="char">0 (0)</td><td align="char">7 (33.3)</td></tr><tr><td>WBRT before ASCT</td><td align="char">3 (6.3)</td><td align="char">2 (7.4)</td><td align="char">1 (4.8)</td></tr><tr><td>HD-MTX cycles</td><td/><td/><td/></tr><tr><td>&#x000a0;Median</td><td>4</td><td>4</td><td>4</td></tr><tr><td>&#x000a0;Range</td><td>0-14</td><td>2-14</td><td>0-10</td></tr><tr><td>HD-MTX cycles for PCNSL in CR1</td><td>NA</td><td/><td>NA</td></tr><tr><td>&#x000a0;Median</td><td/><td>4</td><td/></tr><tr><td>&#x000a0;Range</td><td/><td>2-13</td><td/></tr><tr><td>Ara-C/thiotepa cycles</td><td/><td/><td/></tr><tr><td>&#x000a0;Median</td><td>1</td><td>2</td><td>0</td></tr><tr><td>&#x000a0;Range</td><td>0-3</td><td>0-2</td><td>0-3</td></tr><tr><td>Ara-C/thiotepa cycles for PCNSL in CR1</td><td>NA</td><td/><td>NA</td></tr><tr><td>&#x000a0;Median</td><td/><td>2</td><td/></tr><tr><td>&#x000a0;Range</td><td/><td>1-2</td><td/></tr></tbody></table><table-wrap-foot><fn id="tspara0015"><p>Data presented as n (%).</p></fn><fn id="tspara0020"><p>Abbreviations: ASCT&#x000a0;= autologous stem cell transplantation; CHOEP&#x000a0;= cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone; CR1&#x000a0;= first complete remission; HD-MTX&#x000a0;= high-dose methotrexate; HyperCVAD&#x000a0;= cyclophosphamide, vincristine, doxorubicin, dexamethasone; IT-Ara-C&#x000a0;= intrathecal cytarabine; IT-MTX&#x000a0;= intrathecal methotrexate; NA&#x000a0;= not applicable; PCNSL&#x000a0;= primary central nervous system lymphoma; PR&#x000a0;= partial response; R-CHOP&#x000a0;= rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; R-DHAOx&#x000a0;= rituximab, dexamethasone, high-dose cytarabine, oxaliplatin; R-DHAP&#x000a0;= rituximab, dexamethasone, cytarabine, cisplatin; R-EPOCH&#x000a0;= rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; SCNSL&#x000a0;= secondary central nervous system lymphoma; WBRT&#x000a0;= whole brain radiation therapy.</p></fn></table-wrap-foot></table-wrap></p><p id="p0035">HDC before ASCT consisted of thiotepa 250 mg/m<sup>2</sup> daily for 3&#x000a0;doses on days&#x000a0;&#x02212;9 to&#x000a0;&#x02212;7, busulfan 0.8 mg/kg every 6 hours for 12&#x000a0;doses on days&#x000a0;&#x02212;6 to&#x000a0;&#x02212;4, and cyclophosphamide 60 mg/kg daily for 2 doses on days&#x000a0;&#x02212;3 and&#x000a0;&#x02212;2, with mesna, as previously described by Soussain et&#x000a0;al.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> Phenytoin 300 mg daily was given for seizure prophylaxis on days&#x000a0;&#x02212;7 to&#x000a0;&#x02212;2. Peripheral blood stem cells were mobilized and collected per institution protocol.</p></sec><sec id="sec2.3"><title>Toxicity Evaluation</title><p id="p0040">Toxicity was assessed via medical record review. Neutrophil and platelet recovery were assessed according to the Center for International Blood and Marrow Transplant Research (available at: <ext-link ext-link-type="uri" xlink:href="https://www.cibmtr.org/DataManagement/TrainingReference/Manuals/DataManagement/Documents/post-ted-instruction.pdf" id="intref0010">https://www.cibmtr.org/DataManagement/TrainingReference/Manuals/DataManagement/Documents/post-ted-instruction.pdf</ext-link>). Neutrophil engraftment was defined as the first of 3 consecutive days with an absolute neutrophil count of&#x000a0;&#x02265; 500 cells/mm<sup>2</sup>. Platelet recovery was defined as the first of 3 consecutive days with a platelet count of&#x000a0;&#x02265; 20,000/mm<sup>2</sup> that was 7 days after the last platelet transfusion. Treatment-related mortality (TRM) was defined as death from any cause other than disease relapse within 100 days after ASCT.</p></sec><sec id="sec2.4"><title>Survival</title><p id="p0045">The Kaplan-Meier method was used to plot the survival curves. Progression-free survival (PFS) was defined from the date of ASCT to the date of relapse, progression, or death from any cause. Overall survival (OS) was calculated from the date of ASCT to death from any cause. The date of disease progression was assigned using the date of the imaging study or biopsy, if available, to confirm disease progression.</p></sec><sec id="sec2.5"><title>Statistical Analysis</title><p id="p0050">Data are summarized as the mean &#x000b1; standard deviation, median and interquartile range, or number in the group with the percentage of the group, according to the distribution of the data. Univariate comparisons between diagnoses were performed using Fisher&#x02019;s exact test for discrete data and the Wilcoxon rank sum test for continuous data. OS and PFS were modeled using the Cox proportional hazards model and summarized using hazard ratios (HRs) and 95% confidence intervals (CIs). Time-to-event data were further summarized using Kaplan-Meier curves. All hypotheses were 2-sided, and <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;.05 was considered to indicate statistical significance. Analyses were completed using the R Statistical Computing Environment (R Core Team; R Foundation, Vienna, Austria).</p></sec></sec><sec id="sec3"><title>Results</title><sec id="sec3.1"><title>Patient Characteristics</title><p id="p0055">From July 2006 to December 2017, 48 consecutive patients with NHL were identified who had undergone ASCT with TBC conditioning. Of these 48 patients, 27 had PCNSL (2 of whom had intraocular lymphoma) and 21 had either relapsed disease with CNS involvement (13 patients) or SCNSL (8 patients). The median follow-up time after ASCT was 23.9 months (interquartile range [IQR], 8.4-59.5 months). Of the 27 patients with PCNSL, 21 had undergone ASCT in CR1. Of the secondary CNSL/CNS relapse group, 17 patients had diffuse large B-cell lymphoma, 1 had anaplastic large cell lymphoma, 1 had primary effusion lymphoma, and 2 had peripheral T-cell lymphoma.</p><p id="p0060">The patient characteristics are listed in <xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>
. The median age of the patients at ASCT was 59.4 years (IQR, 52.1-66.2 years). Of the 48 patients, 23 were women and 25 were men. Two patients had human immunodeficiency virus. Among the total 48 patients, 22 patients had non-germinal center B cell (GCB), 14 patients had GCB, 8 patients had unknown phenotype, and 4 were not applicable. Most patients had a Karnofsky score at ASCT of&#x000a0;&#x02265; 80 (67.0%). Overall, 29 patients (60.0%) had undergone ASCT in CR1 and 19 patients (40.0%) had undergone ASCT not in CR1. Of these 19 patients, 3 had undergone ASCT in partial response (all with PCNSL) and 16 had undergone ASCT in the second or third CR.<table-wrap position="float" id="tbl2"><label>Table&#x000a0;2</label><caption><p>Patient Characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Characteristic</th><th>All Patients (n&#x000a0;= 48)</th><th>PCNSL (n&#x000a0;= 27)</th><th>SCNSL/CNS Relapse (n&#x000a0;= 21)</th><th><italic>P</italic> Value</th></tr></thead><tbody><tr><td>Age at diagnosis, y</td><td/><td/><td/><td align="char">.51</td></tr><tr><td>&#x000a0;Median</td><td>58.0</td><td>56.7</td><td>61.4</td><td/></tr><tr><td>&#x000a0;IQR</td><td>50.4-64.8</td><td>49.9-63.9</td><td>50.8-65.1</td><td/></tr><tr><td>Age group</td><td/><td/><td/><td align="char">.56</td></tr><tr><td>&#x000a0;&#x02264;60 y</td><td align="char">26 (54)</td><td align="char">16 (59.3)</td><td align="char">10 (47.6)</td><td/></tr><tr><td>&#x000a0;&#x0003e;60 y</td><td align="char">22 (46)</td><td align="char">11 (40.7)</td><td align="char">11 (52.4)</td><td/></tr><tr><td>Age at ASCT, y</td><td/><td/><td/><td align="char">.33</td></tr><tr><td>&#x000a0;Median</td><td>59.4</td><td>57.2</td><td>62.0</td><td/></tr><tr><td>&#x000a0;IQR</td><td>52.1-66.2</td><td>50.6-64.8</td><td>53.5-67.3</td><td/></tr><tr><td>Age group</td><td/><td/><td/><td align="char">.77</td></tr><tr><td>&#x000a0;&#x02264;60 y</td><td align="char">25 (52.0)</td><td align="char">15 (55.6)</td><td align="char">10 (47.6)</td><td/></tr><tr><td>&#x000a0;&#x0003e;60 y</td><td align="char">23 (48.0)</td><td align="char">12 (44.4)</td><td align="char">11 (52.4)</td><td/></tr><tr><td>Gender</td><td/><td/><td/><td align="char">.77</td></tr><tr><td>&#x000a0;Female</td><td align="char">23 (48.0)</td><td align="char">12 (44.4)</td><td align="char">11 (52.4)</td><td/></tr><tr><td>&#x000a0;Male</td><td align="char">25 (52.0)</td><td align="char">15 (55.6)</td><td align="char">10 (47.6)</td><td/></tr><tr><td>Ethnicity</td><td/><td/><td/><td/></tr><tr><td>&#x000a0;White</td><td align="char">20 (42.0)</td><td align="char">11 (40.7)</td><td align="char">9 (42.9)</td><td align="char">.58</td></tr><tr><td>&#x000a0;Hispanic</td><td align="char">10 (21.0)</td><td align="char">5 (18.5)</td><td align="char">5 (23.8)</td><td/></tr><tr><td>&#x000a0;Asian</td><td align="char">6 (12.0)</td><td align="char">5 (18.5)</td><td align="char">1 (4.8)</td><td/></tr><tr><td>&#x000a0;Other</td><td align="char">12 (25.0)</td><td align="char">6 (22.2)</td><td align="char">6 (28.6)</td><td/></tr><tr><td>HIV status</td><td/><td/><td/><td/></tr><tr><td>&#x000a0;Negative</td><td align="char">46 (96.0)</td><td align="char">27 (100.0)</td><td align="char">19 (90.5)</td><td align="char">.19</td></tr><tr><td>&#x000a0;Positive</td><td align="char">2 (4.0)</td><td align="char">0 (0)</td><td align="char">2 (9.5)</td><td/></tr><tr><td>Cell of origin</td><td/><td/><td/><td/></tr><tr><td>&#x000a0;GCB</td><td align="char">14 (29.0)</td><td align="char">7 (25.9)</td><td align="char">7 (33.3)</td><td align="char">.072</td></tr><tr><td>&#x000a0;Non-GCB</td><td align="char">22 (46.0)</td><td align="char">15 (55.6)</td><td align="char">7 (33.3)</td><td/></tr><tr><td>&#x000a0;Unknown</td><td align="char">8 (17.0)</td><td align="char">5 (18.5)</td><td align="char">3 (14.3)</td><td/></tr><tr><td>&#x000a0;NA</td><td align="char">4 (8.0)</td><td align="char">0 (0)</td><td align="char">4 (19.0)</td><td/></tr><tr><td>Karnofsky score at ASCT</td><td/><td/><td/><td/></tr><tr><td>&#x000a0;&#x0003c;80</td><td align="char">16 (33.0)</td><td align="char">10 (37.0)</td><td align="char">6 (28.6)</td><td align="char">.76</td></tr><tr><td>&#x000a0;&#x02265;80</td><td align="char">32 (67.0)</td><td align="char">17 (63.0)</td><td align="char">15 (71.4)</td><td/></tr><tr><td>Disease status at ASCT</td><td/><td/><td/><td align="char">.008</td></tr><tr><td>&#x000a0;CR1</td><td align="char">29 (60)</td><td align="char">21 (77.8)</td><td align="char">8 (38.1)</td><td/></tr><tr><td>&#x000a0;Beyond CR1 or PR</td><td align="char">19 (40)</td><td align="char">6 (22.2)</td><td align="char">13 (61.9)</td><td/></tr><tr><td>Interval from diagnosis to ASCT, mo</td><td/><td/><td/><td align="char">.001</td></tr><tr><td>&#x000a0;Median</td><td>7.0</td><td>6.2</td><td>16.0</td><td/></tr><tr><td>&#x000a0;IQR</td><td>5.2-16.1</td><td>4.7-9.5</td><td>7.0-25.3</td><td/></tr><tr><td>Follow-up after ASCT, mo</td><td/><td/><td/><td align="char">.33</td></tr><tr><td>&#x000a0;Median</td><td>23.9</td><td>30.2</td><td>18.1</td><td/></tr><tr><td>&#x000a0;IQR</td><td>8.4-59.5</td><td>8.9-64.8</td><td>5.5-50.9</td><td/></tr></tbody></table><table-wrap-foot><fn id="tspara0030"><p>Data presented as n (%).</p></fn><fn id="tspara0035"><p>Abbreviations: ASCT&#x000a0;= autologous stem cell transplantation; CR1&#x000a0;= first complete remission; GCB&#x000a0;= germinal center B cell; HIV&#x000a0;= human immunodeficiency virus; IQR&#x000a0;= interquartile range; PCNSL&#x000a0;= primary central nervous system lymphoma; PR&#x000a0;= partial response; SCNSL&#x000a0;= secondary central nervous system lymphoma.</p></fn></table-wrap-foot></table-wrap></p><p id="p0065">The median time from the original diagnosis to ASCT for all patients was 7.0 months (IQR, 5.2-16.1 months). For those patients with PCNSL, the median time was 6.2 months (IQR, 4.7-9.5 months) compared with 16.0 months (IQR, 7.0-25.3) for those with SCNSL or CNS relapse (<italic>P</italic>&#x000a0;= .001).</p></sec><sec id="sec3.2"><title>Pretransplant Therapies</title><p id="p0070">The chemotherapy regimens used for all patients before ASCT are listed in <xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>. Of the 21 patients with PCNSL who had undergone ASCT in CR1, all had received induction therapy with rituximab/HD-MTX for a various number of cycles as determined by the treating physicians (median, 4; range, 2-13), followed by rituximab/cytarabine/thiotepa (median, 2; range, 0-2). One patient with PCNSL did not receive thiotepa with rituximab/cytarabine for unclear reasons. The other 6 patients with relapsed or refractory disease before ASCT had received additional therapies, including temozolomide (3 patients) and topotecan (1 patient), in addition to extra cycles of rituximab/HD-MTX and rituximab/cytarabine/thiotepa.</p><p id="p0075">The patients with SCNSL/CNS relapse had received a variety of therapies before ASCT, including R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; 6 patients; 28.6%), R-EPOCH (rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; 9 patients; 42.9%), and R-DHAP (rituximab, dexamethasone, cytarabine, cisplatin; 6 patients; 28.6%), in addition to other regimens, including R-DHAOx (rituximab, dexamethasone, high-dose cytarabine, oxaliplatin), HyperCVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone), CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone), temozolomide, and belinostat. HD-MTX (14 patients; 66.7%) and HD-cytarabine (4 patients; 19.0%) were also given, and intrathecal chemotherapy with IT-MTX (intrathecal methotrexate) and/or intrathecal cytarabine were administered to 7 patients.</p><p id="p0080">The median number of cycles of HD-MTX for all patients was 4&#x000a0;(range, 0-14), and the median number of cycles of cytarabine/thiotepa for all patients was 1 (range, 0-3). Three patients received WBRT before ASCT, including 2 patients with PCNSL without remission after induction chemotherapy and 1 patient with CNS relapse.</p></sec><sec id="sec3.3"><title>Transplant Outcomes</title><p id="p0085">The Kaplan-Meier curves for PFS and OS are displayed in <xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>
. For all 48 patients, the 2-year PFS rate was 80.5% (95% CI, 69.9%-92.9%) and the 2-year OS rate was 80.1% (95% CI, 69.2%-92.7%). The 2-year PFS rate for the patients with PCNSL and SCNSL/CNS relapse was 84.2% (95% CI, 71.0%-99.8%) and 75.9% (95% CI, 59.5%-96.8%), respectively. The 2-year OS rate for patients with PCNSL and SCNSL/CNS relapse was 83.6% (95% CI, 70.1%-99.8%) and 75.3% (95% CI, 58.6%-96.8%), respectively (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>). The 2-year PFS and OS rate for PCNSL patients in CR1 was 95.2% (95% CI, 86.6%-100%) and 95.2% (95% CI, 86.6%-100%), respectively. For PCNSL patients not in CR1, the median PFS was 1.85 years and the median OS was 1.87 years. The median PFS was not reached for any other patient group (PCNSL patients in CR1 and those with SCNSL/CNS relapse). Only 2 patients had developed a relapse &#x0003e; 1 year after ASCT (1 patient with PCNSL and 1 patient with CNS relapse).<fig id="fig1"><label>Figure&#x000a0;1</label><caption><p>Kaplan-Meier Curves of Progression-free Survival and Overall Survival According to Subgroup. (<bold>A</bold>) Progression-free Survival of Patients With Primary Central Nervous System Lymphoma (PCNSL) According to Transplantation in First Complete Response (CR1). (<bold>B</bold>) Overall Survival in Patients With PCNSL According to Transplantation in CR1. (<bold>C</bold>) Progression-free Survival of Patients With Secondary Central Nervous System (CNS) Lymphoma (SCNSL)/CNS Relapse. (<bold>D</bold>) Overall Survival for Patients With SCNSL/CNS Relapse</p></caption><graphic xlink:href="gr1ab_lrg"/><graphic xlink:href="gr1cd_lrg"/></fig></p><p id="p0090">On univariate analysis of the patients with PCNSL (<xref rid="tbl3" ref-type="table">Table&#x000a0;3</xref>
), ASCT in CR1 versus not in CR1 was the only statistically significant variable (PFS: HR, 13.36; 95% CI, 1.48-120.18, <italic>P</italic>&#x000a0;= .007; OS: HR, 12.89; 95% CI, 1.43-115.88; <italic>P</italic>&#x000a0;= .008). On univariate analysis of SCNSL/CNS relapse (<xref rid="tbl4" ref-type="table">Table&#x000a0;4</xref>
), patient age&#x000a0;&#x02264; 60 years and Karnofsky score&#x000a0;&#x0003c; 80 were statistically significant factors for PFS (patient age: HR, 6.55; 95% CI, 0.75-57.22; <italic>P</italic>&#x000a0;= .046; Karnofsky score: HR, 0.17; 95% CI, 0.03-0.94; <italic>P</italic>&#x000a0;= .036) but not for OS (age: HR, 4.22; 95% CI, 0.47-37.84; <italic>P</italic>&#x000a0;= .148; Karnofsky score: HR, 0.22; 95% CI, 0.04-1.32; <italic>P</italic>&#x000a0;= .097).<table-wrap position="float" id="tbl3"><label>Table&#x000a0;3</label><caption><p>Univariable Cox Proportional Hazard Regression Analysis for PFS and OS in PCNSL</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Parameter</th><th colspan="2">PFS<hr/></th><th colspan="2">OS<hr/></th></tr><tr><th>HR (95% CI)</th><th><italic>P</italic> Value</th><th>HR (95% CI)</th><th><italic>P</italic> Value</th></tr></thead><tbody><tr><td>Gender</td><td/><td align="char">.185</td><td/><td align="char">.192</td></tr><tr><td>&#x000a0;Female</td><td>Reference</td><td/><td>Reference</td><td/></tr><tr><td>&#x000a0;Male</td><td align="char">3.77 (0.42-33.8)</td><td/><td align="char">3.70 (0.41-33.15)</td><td/></tr><tr><td>Ethnicity</td><td/><td align="char">.092</td><td/><td align="char">.102</td></tr><tr><td>&#x000a0;Other</td><td>Reference</td><td/><td>Reference</td><td/></tr><tr><td>&#x000a0;White</td><td align="char">5.35 (0.59-48.55)</td><td/><td align="char">5.10 (0.56-46.17)</td><td/></tr><tr><td>Age, y</td><td/><td align="char">.061</td><td/><td align="char">.051</td></tr><tr><td>&#x000a0;&#x02264;60</td><td>Reference</td><td/><td>Reference</td><td/></tr><tr><td>&#x000a0;&#x0003e;60</td><td align="char">6.32 (0.70-57.04)</td><td/><td align="char">6.79 (0.75-61.23)</td><td/></tr><tr><td>Karnofsky score</td><td/><td align="char">.060</td><td/><td align="char">.067</td></tr><tr><td>&#x000a0;&#x0003c;80</td><td>Reference</td><td/><td>Reference</td><td/></tr><tr><td>&#x000a0;&#x02265;80</td><td align="char">0.16 (0.02-1.42)</td><td/><td align="char">0.17 (0.02-1.49)</td><td/></tr><tr><td>Transplant in CR1</td><td/><td align="char">.007</td><td/><td align="char">.008</td></tr><tr><td>&#x000a0;No</td><td>Reference</td><td/><td>Reference</td><td/></tr><tr><td>&#x000a0;Yes</td><td align="char">13.36 (1.48-120.18)</td><td/><td align="char">12.89 (1.43-115.88)</td><td/></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: CI&#x000a0;= confidence interval; CR1&#x000a0;= first complete remission; HR&#x000a0;= hazard ratio; OS&#x000a0;= overall survival; PCNSL&#x000a0;= primary central nervous system lymphoma; PFS&#x000a0;= progression-free survival.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl4"><label>Table&#x000a0;4</label><caption><p>Univariable Cox Proportional Hazard Regression Analysis for PFS and OS in SCNSL/CNS Relapse</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Parameter</th><th colspan="2">PFS<hr/></th><th colspan="2">OS<hr/></th></tr><tr><th>HR (95% CI)</th><th><italic>P</italic> Value</th><th>HR (95% CI)</th><th><italic>P</italic> Value</th></tr></thead><tbody><tr><td>Gender</td><td/><td align="char">.997</td><td/><td align="char">.592</td></tr><tr><td>&#x000a0;Female</td><td>Reference</td><td/><td>Reference</td><td/></tr><tr><td>&#x000a0;Male</td><td align="char">1.0 (0.20-5.12)</td><td/><td align="char">1.62 (0.27-9.74)</td><td/></tr><tr><td>Ethnicity</td><td/><td align="char">.523</td><td/><td align="char">.263</td></tr><tr><td>&#x000a0;Other</td><td>Reference</td><td/><td>Reference</td><td/></tr><tr><td>&#x000a0;White</td><td align="char">0.58 (0.11-3.20)</td><td/><td align="char">0.32 (0.04-2.88)</td><td/></tr><tr><td>Age, y</td><td/><td align="char">.046</td><td/><td align="char">.148</td></tr><tr><td>&#x000a0;&#x02264;60</td><td>Reference</td><td/><td>Reference</td><td/></tr><tr><td>&#x000a0;&#x0003e;60</td><td align="char">6.55 (0.75-57.22)</td><td/><td align="char">4.22 (0.47-37.84)</td><td/></tr><tr><td>Karnofsky score</td><td/><td align="char">.036</td><td/><td align="char">.097</td></tr><tr><td>&#x000a0;&#x0003c;80</td><td>Reference</td><td/><td>Reference</td><td/></tr><tr><td>&#x000a0;&#x02265;80</td><td align="char">0.17 (0.03-0.94)</td><td/><td align="char">0.22 (0.04-1.32)</td><td/></tr><tr><td>Transplantation in CR1</td><td/><td align="char">.263</td><td/><td align="char">.178</td></tr><tr><td>&#x000a0;No</td><td>Reference</td><td/><td>Reference</td><td/></tr><tr><td>&#x000a0;Yes</td><td align="char">2.58 (0.50-13.23)</td><td/><td align="char">3.41 (0.56-20.66)</td><td/></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: CI&#x000a0;= confidence interval; CNS&#x000a0;= central nervous system; CR1&#x000a0;= first complete remission; HR&#x000a0;= hazard ratio; OS&#x000a0;= overall survival; PFS&#x000a0;= progression-free survival; SCNSL&#x000a0;= secondary central nervous system lymphoma.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec3.4"><title>ASCT-related Toxicities</title><p id="p0095">The ASCT-related toxicities that occurred with the TBC conditioning regimen are listed in <xref rid="tbl5" ref-type="table">Table&#x000a0;5</xref>
. The median interval to neutrophil recovery and platelet recovery was 9.5 days (IQR, 9.0-10.0 days) and 15.0 days (IQR, 12.5-19.5 days), respectively. Most patients (89.6%) experienced febrile neutropenia, and 66.7% were found to have infection. Bacterial infection was present in 58.3% and included pneumonia (18.8%), colitis (16.7%; 10.4% with <italic>Clostridium difficile</italic>), bacteremia (10.4%; with organisms that included <italic>Escherichia coli</italic>, <italic>Staphylococcus epidermidis</italic>, and coagulase-negative staphylococcus), urinary tract infection (6.3%; with organisms that included coagulase-negative staphylococcus and <italic>E.&#x000a0;coli</italic>), and sinusitis (2.1%). Viral infection was present in 45.8% of patients, including 33.3% with herpes simplex virus mucositis, 2.1% with herpes simplex virus vaginitis, 2.1% with coronavirus, 2.1% with rhinovirus, 2.1% with parainfluenza, 2.1% with human herpesvirus 6 bacteremia, and 2.1% with viral pneumonia. Fungal infection was present in 8.3% of patients, including 6.3% with <italic>Candida glabrata</italic> urinary tract infection and 2.1% with <italic>Candida dubliniensis</italic> bacteremia. Almost all patients developed nausea and vomiting (85.4%) and diarrhea (93.8%). Mucositis was present in 89.6% of patients; 35.4% with grade 3 or higher. Dermatologic sequelae, including rashes, bullae, desquamation, discoloration, and pruritus, were found in 31.3% of the patients. Acute neurotoxicity occurred in 27.1% of patients, with 4.2% developing seizure. Four patients (8.3%) developed hemorrhagic cystitis as a result of cyclophosphamide. Renal injury occurred in 16.7% of patients, and electrolyte abnormalities occurred in 89.6% of patients. Cardiac toxicity developed in 16.7% of patients, including 2.1% with cardiomyopathy presumed secondary to cyclophosphamide and 14.6% with arrhythmia that included supraventricular tachycardia and atrial fibrillation with a rapid ventricular response. Liver function abnormalities occurred in 18.8% of patients. Four patients (8.3%) died of treatment-related causes resulting from overwhelming infection, 3 of whom had SCNSL. All 4 patients had died within 1.5 months after ASCT. No evidence of pulmonary toxicity or veno-occlusive disease was noted.<table-wrap position="float" id="tbl5"><label>Table&#x000a0;5</label><caption><p>ASCT Toxicity With TBC Conditioning Regimen</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>All Patients (n&#x000a0;= 48)</th><th>PCNSL (n&#x000a0;= 27)</th><th>SCNSL/CNS Relapse (n&#x000a0;= 21)</th></tr></thead><tbody><tr><td>Interval to neutrophil recovery, d</td><td/><td/><td/></tr><tr><td>&#x000a0;Median</td><td>9.5</td><td>9.0</td><td>10.0</td></tr><tr><td>&#x000a0;IQR</td><td>9.0-10.0</td><td>8.0-10.0</td><td>9.0-10.0</td></tr><tr><td>Interval to platelet recovery, d</td><td/><td/><td/></tr><tr><td>&#x000a0;Median</td><td>15.0</td><td>15.0</td><td>14.0</td></tr><tr><td>&#x000a0;IQR</td><td>12.5-19.5</td><td>14.0-21.0</td><td>11.0-16.0</td></tr><tr><td>Toxicity</td><td/><td/><td/></tr><tr><td>&#x000a0;Febrile neutropenia</td><td align="char">43 (89.6)</td><td align="char">25 (52.1)</td><td align="char">18 (37.5)</td></tr><tr><td>&#x000a0;Infection</td><td align="char">32 (66.7)</td><td align="char">18 (37.5)</td><td align="char">14 (29.2)</td></tr><tr><td>&#x000a0;Bacterial</td><td align="char">28 (58.3)</td><td align="char">20 (41.7)</td><td align="char">8 (16.7)</td></tr><tr><td>&#x000a0;Viral</td><td align="char">22 (45.8)</td><td align="char">10 (20.8)</td><td align="char">12 (25.0)</td></tr><tr><td>&#x000a0;Fungal</td><td align="char">4 (8.3)</td><td align="char">3 (6.3)</td><td align="char">1 (2.1)</td></tr><tr><td>&#x000a0;Nausea/vomiting</td><td align="char">41 (85.4)</td><td align="char">22 (45.8)</td><td align="char">19 (39.6)</td></tr><tr><td>&#x000a0;Diarrhea</td><td align="char">45 (93.8)</td><td align="char">26 (54.2)</td><td align="char">19 (39.6)</td></tr><tr><td>&#x000a0;Mucositis</td><td align="char">43 (89.6)</td><td align="char">22 (45.8)</td><td align="char">21 (43.8)</td></tr><tr><td>&#x000a0;Grade 1 or 2</td><td align="char">26 (54.2)</td><td align="char">12 (25.0)</td><td align="char">14 (29.2)</td></tr><tr><td>&#x000a0;Grade 3 or 4</td><td align="char">17 (35.4)</td><td align="char">10 (20.8)</td><td align="char">7 (14.6)</td></tr><tr><td>&#x000a0;Dermatologic</td><td align="char">15 (31.3)</td><td align="char">15 (31.3)</td><td align="char">0 (0)</td></tr><tr><td>&#x000a0;Acute neurotoxicity</td><td align="char">13 (27.1)</td><td align="char">10 (20.8)</td><td align="char">3 (6.3)</td></tr><tr><td>&#x000a0;AMS/delirium</td><td align="char">13 (27.1)</td><td align="char">10 (20.8)</td><td align="char">3 (6.3)</td></tr><tr><td>&#x000a0;Seizure</td><td align="char">2 (4.2)</td><td align="char">1 (2.1)</td><td align="char">1 (2.1)</td></tr><tr><td>&#x000a0;Hemorrhagic cystitis</td><td align="char">4 (8.3)</td><td align="char">2 (4.2)</td><td align="char">2 (4.2)</td></tr><tr><td>&#x000a0;Renal injury</td><td align="char">8 (16.7)</td><td align="char">3 (6.3)</td><td align="char">5 (10.4)</td></tr><tr><td>&#x000a0;Electrolyte abnormalities</td><td align="char">43 (89.6)</td><td align="char">24 (50.0)</td><td align="char">19 (39.6)</td></tr><tr><td>&#x000a0;Hypokalemia</td><td align="char">38 (79.2)</td><td align="char">22 (45.8)</td><td align="char">16 (33.3)</td></tr><tr><td>&#x000a0;Hypomagnesemia</td><td align="char">7 (14.6)</td><td align="char">1 (2.1)</td><td align="char">6 (12.5)</td></tr><tr><td>&#x000a0;Hypophosphatemia</td><td align="char">18 (37.5)</td><td align="char">9 (18.8)</td><td align="char">9 (18.8)</td></tr><tr><td>&#x000a0;Hyponatremia</td><td align="char">8 (16.7)</td><td align="char">3 (6.3)</td><td align="char">5 (10.4)</td></tr><tr><td>&#x000a0;Hypernatremia</td><td align="char">6 (12.5)</td><td align="char">4 (8.3)</td><td align="char">2 (4.2)</td></tr><tr><td>&#x000a0;Metabolic alkalosis</td><td align="char">4 (8.3)</td><td align="char">1 (2.1)</td><td align="char">3 (6.3)</td></tr><tr><td>&#x000a0;Metabolic acidosis</td><td align="char">6 (12.5)</td><td align="char">4 (8.3)</td><td align="char">2 (4.2)</td></tr><tr><td>&#x000a0;Cardiac</td><td align="char">8 (16.7)</td><td align="char">5 (10.4)</td><td align="char">3 (6.3)</td></tr><tr><td>&#x000a0;Cardiomyopathy</td><td align="char">1 (2.1)</td><td align="char">0 (0)</td><td align="char">1 (2.1)</td></tr><tr><td>&#x000a0;Arrhythmia</td><td align="char">7 (14.6)</td><td align="char">5 (10.4)</td><td align="char">2 (4.2)</td></tr><tr><td>&#x000a0;Liver function abnormalities</td><td align="char">9 (18.8)</td><td align="char">8 (16.7)</td><td align="char">1 (2.1)</td></tr><tr><td>&#x000a0;Respiratory compromise</td><td align="char">4 (8.3)</td><td align="char">1 (2.1)</td><td align="char">3 (6.3)</td></tr><tr><td>&#x000a0;Transplant-related mortality</td><td align="char">4 (8.3)</td><td align="char">1 (2.1)</td><td align="char">3 (6.3)</td></tr></tbody></table><table-wrap-foot><fn id="tspara0065"><p>Data presented as n (%).</p></fn><fn id="tspara0070"><p>Abbreviations: AMS&#x000a0;= altered mental status; ASCT&#x000a0;= autologous stem cell transplantation; CNS&#x000a0;= central nervous system; IQR&#x000a0;= interquartile range; PCNSL&#x000a0;= primary central nervous system lymphoma; SCNSL&#x000a0;= secondary central nervous system lymphoma; TBC&#x000a0;= thiotepa, busulfan, cyclophosphamide.</p></fn></table-wrap-foot></table-wrap></p></sec></sec><sec id="sec4"><title>Discussion</title><p id="p0100">Despite data that support the use of HDC/ASCT for patients with NHL involving the CNS as both postremission consolidation<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref>
<sup>,</sup>
<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref>
<sup>,</sup>
<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref>
<sup>,</sup>
<xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib11" ref-type="bibr">11</xref>, <xref rid="bib12" ref-type="bibr">12</xref>, <xref rid="bib13" ref-type="bibr">13</xref>, <xref rid="bib14" ref-type="bibr">14</xref>, <xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib16" ref-type="bibr">16</xref>, <xref rid="bib17" ref-type="bibr">17</xref>, <xref rid="bib18" ref-type="bibr">18</xref>
<sup>,</sup>
<xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib22" ref-type="bibr">22</xref>, <xref rid="bib23" ref-type="bibr">23</xref>, <xref rid="bib24" ref-type="bibr">24</xref>, <xref rid="bib25" ref-type="bibr">25</xref>, <xref rid="bib26" ref-type="bibr">26</xref> and in the relapsed/refractory setting,<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref>
<sup>,</sup>
<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref>
<sup>,</sup>
<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref>
<sup>,</sup>
<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref>
<sup>,</sup>
<xref rid="bib28" ref-type="bibr">28</xref>, <xref rid="bib29" ref-type="bibr">29</xref>, <xref rid="bib30" ref-type="bibr">30</xref> several unanswered questions remain regarding the ideal patient candidates, optimal conditioning, and timing of transplantation. Furthermore, the efficacy and toxicity compared with those of WBRT or nonmyeloablative chemotherapy are incompletely characterized.<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref> Our study, which evaluated HDC/ASCT in the postremission and relapsed/refractory settings using a uniform TBC preparative regimen, in accordance with previously reported data by Soussain et&#x000a0;al,<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref>
<sup>,</sup>
<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref>
<sup>,</sup>
<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> aimed to provide insight for identifying patients who might benefit most from this therapy.</p><p id="p0105">The first trials examining HDC/ASCT for PCNSL used the BEAM (carmustine, etoposide, cytarabine, melphalan) conditioning regimen with disappointing results.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref>
<sup>,</sup>
<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref>
<sup>,</sup>
<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> Abrey et&#x000a0;al<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> reported a relapse rate of 57.1% at a median of 2.3 months after transplant using BEAM conditioning. Colombat et&#x000a0;al<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> reported a projected event-free survival (EFS) rate of 66% at 3 years and a projected OS rate of 64% at 4 years. These results, in part, were attributed to the limited penetration of the blood&#x02013;brain barrier by BEAM chemotherapy and led to trials investigating busulfan and thiotepa, both reported to have CNS penetration of &#x0003e; 80%, as alternative myeloablative agents.<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref>
<sup>,</sup>
<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref> Studies of TBC have shown higher efficacy than that with BEAM conditioning. Omuro et&#x000a0;al<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> reported a PFS and an OS rate of 85% (95% CI, 64%-94%) and 88% (95% CI, 68%-96%) at 1 year after ASCT for patients with PCNSL, respectively. Chen et&#x000a0;al<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> reported a PFS and an OS rate of 81% (95% CI, 59%-92%) and 93% (95% CI, 76%-98%) at 2 years after ASCT in a cohort of patients with PCNSL and SCNSL, respectively. Our data add to these findings, with disease control and survival rates comparable to those reported in these studies, with a 2-year PFS rate of 80.5% (95% CI, 69.9%-92.9%) and 2-year OS rate of 80.1% (95% CI, 69.2%-92.7%).</p><p id="p0110">In the subset of patients with PCNSL who had undergone ASCT in CR1, the data might be even more favorable, with our institution reporting a 2-year PFS and OS rate of 95.2% (95% CI, 86.6%-100%). These results mimic the data reported by DeFilipp et&#x000a0;al,<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> which noted PFS and OS of 92% and 95% at 2 years for patients with PCNSL who had undergone transplantation in CR1. Furthermore, on univariate analysis of the data from patients with PCNSL, ASCT in CR1 was the only variable that was statistically significant for PFS (HR, 13.36; 95% CI, 1.48-120.18; <italic>P</italic>&#x000a0;= .007) or OS (HR, 12.89; 95% CI, 1.43-115.88; <italic>P</italic>&#x000a0;= .008). These data are not surprising, given the clear survival benefit and lower relapse rates for patients with NHL in CR before ASCT.<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref>
<sup>,</sup>
<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref>
</p><p id="p0115">Of the patients with SCNSL and CNS-relapsed NHL who had undergone ASCT with TBC conditioning, the 2-year PFS and OS rates in our study were 75.9% (95% CI, 59.5%-96.8%) and 75.3% (95% CI, 58.6%-96.8%), respectively. These findings are equivalent or superior to the results reported by other studies and compare favorably with the results for patients with relapsed/refractory PCNSL and intraocular lymphoma.<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> In a subset analysis of 12 patients with SCNSL who had undergone HDC/ASCT, also with TBC conditioning, Chen et&#x000a0;al<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> reported 2-year PFS and OS of 51% (95% CI, 18%-77%) and 83% (95% CI, 48%-96%), respectively. Another study by Qualls et&#x000a0;al<xref rid="bib36" ref-type="bibr"><sup>36</sup></xref> of 20 patients with SCNSL who had also undergone HDC/ASCT with TBC conditioning reported a 4-year PFS and OS rate of 77% (95% CI, 48%-91%) and 82% (95% CI, 54%-94%), respectively. Given that CNS involvement by NHL has historically been associated with poor outcomes,<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref>
<sup>,</sup>
<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref> our data are encouraging and demonstrate that HDC/ASCT can be safe and efficacious for these patients. Maziarz et&#x000a0;al<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref> conducted a large analysis of 151 patients and noted comparable long-term outcomes for patients with NHL with and without CNS involvement who had undergone ASCT. Other studies have reported less impressive results, with a noted EFS rate of 46% &#x000b1; 26% and OS rate of 41% &#x000b1; 28% at 5 years for 13 patients with SCNSL who had undergone HDC/ASCT with carmustine, etoposide, and cyclophosphamide conditioning<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref> and a disease-free survival rate of 23% &#x000b1; 19% at 2 years for 24 patients with SCNSL who had undergone HDC/ASCT with TBC conditioning.<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref> However, both of these studies had included patients with active CNS disease, which is known to result in poorer outcomes than those for patients with CNS lymphoma in remission.<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref>
<sup>,</sup>
<xref rid="bib41" ref-type="bibr"><sup>41</sup></xref> All the patients with SCNSL/CNS relapse in our study and in the study by Chen et&#x000a0;al<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> and Qualls et&#x000a0;al<xref rid="bib36" ref-type="bibr"><sup>36</sup></xref> had undergone transplantation while in CR, which likely contributed to the favorable survival outcomes.</p><p id="p0120">One concern with the TBC regimen is nonhematologic toxicity. The most common therapy-related toxicities noted in most studies using this regimen have been febrile neutropenia, mucositis, and diarrhea.<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref>
<sup>,</sup>
<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref>
<sup>,</sup>
<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> Our study also found a high rate of nausea/vomiting and electrolyte abnormalities. The incidence of septic complications with TBC conditioning appears to be greater than that with other conditioning regimens and has also led to higher rates of treatment-related mortality. In our study, the TRM rate was 8.3% (all from septic complications), and other institutions have reported a range of 0% to 14.3% with TBC conditioning in patients with PCNSL.<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref>
<sup>,</sup>
<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref>
<sup>,</sup>
<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref>
<sup>,</sup>
<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref> The reason for this increased toxicity is not clear. Although some studies have found age &#x0003e; 60 years to be a factor,<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> others have found no such association.<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> Scordo et&#x000a0;al<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> hypothesized that the high TRM rate might be secondary to busulfan if the levels are greater than the therapeutic range. However, they found that patients with elevated first-dose busulfan area under the curve values did not experience more toxicity.<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref>
</p><p id="p0125">Given that CNS penetration of cyclophosphamide is much lower (&#x0003c; 30%) than what can be achieved with thiotepa and busulfan,<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref> the additional benefit is unclear and might instead contribute to increased toxicity. Four patients (8.3%) developed hemorrhagic cystitis in our study. One study by Montemurro et&#x000a0;al,<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> in 2006, examined thiotepa and busulfan without cyclophosphamide for conditioning as postremission consolidation for 16 patients. The estimated 2-year EFS was 45%,<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> and a long-term follow-up study showed an OS rate of 35%.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> They reported a greater relapse rate (4&#x000a0;patients; 25%) than that reported by other studies with TBC conditioning<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref>
<sup>,</sup>
<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> and also a high TRM (2 patients; 12.5%).<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> Neurotoxicity occurred in 88.9% of the patients who had undergone WBRT, although no such cases were reported for patients who had undergone ASCT without previous WBRT. Therefore, the data thus far show no superior outcomes with the removal of cyclophosphamide from the TBC conditioning regimen. However, given that only 1 study has examined thiotepa and busulfan alone and it had a small sample size of only 16 patients, the true benefit of cyclophosphamide remains undetermined.</p><p id="p0130">An alternative option for a CNS-directed conditioning regimen is the combination of carmustine and thiotepa. Carmustine is another agent with substantial CNS penetration (15%-70%), although not as high as busulfan.<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref> Two studies by Illerhaus et&#x000a0;al<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref>
<sup>,</sup>
<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> evaluated this conditioning regimen with favorable results. One study reported a PFS and an OS rate of 83% at 5 years,<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref>
<sup>,</sup>
<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref> and the second study reported a projected PFS rate of 73% and OS rate of 82% at 5&#x000a0;years.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref>
<sup>,</sup>
<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> Both studies reported no TRM, making this regimen another promising treatment option. As discussed in further detail in subsequent paragraphs, the conditioning regimen of carmustine and thiotepa was also evaluated in the randomized study, IELSG32 (International Extranodal Lymphoma Study Group-32), which reported a 2-year OS of 77% and a TRM of 3%.<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref> A meta-analysis of HDC/ASCT for PCNSL found carmustine/thiotepa to be the conditioning regimen with the lowest risk of TRM.<xref rid="bib44" ref-type="bibr"><sup>44</sup></xref> However, the TBC regimen had numerically superior PFS and OS rates.<xref rid="bib44" ref-type="bibr"><sup>44</sup></xref>
</p><p id="p0135">Neurotoxicity appears to be less common with HDC/ASCT than with WBRT consolidation. We found a rate of 27.1% for reversible neurotoxicity, which most commonly consisted of delirium and, rarely, seizure (4.2%). Scordo et&#x000a0;al<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> reported a similar finding of neurotoxicity in 10% of patients (including delirium, seizure, anxiety/depression, neuropathy, syncope, headache, and mania) who had undergone HDC/ASCT. Long-term neurotoxic effects were not evaluated in our study, although other reports have documented some delayed effects.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref>
<sup>,</sup>
<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> However, the rates of long-term neurotoxic effects appear to be lower than those with WBRT, which has been reported as a 5-year cumulative incidence of neurotoxicity of 24%.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref>
<sup>,</sup>
<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref>
<sup>,</sup>
<xref rid="bib45" ref-type="bibr"><sup>45</sup></xref>
<sup>,</sup>
<xref rid="bib46" ref-type="bibr"><sup>46</sup></xref>
</p><p id="p0140">Our study had several limitations, including the limited sample size and its retrospective nature. Although we did not have precise data on the number of patients who had not received HDC/ASCT, the vast majority of patients with these diagnoses in whom we initiated therapy did ultimately undergo ASCT. In our experience, it was rare for patients with these diagnoses to not be candidates for ASCT after receiving induction or salvage therapy once they had achieved a best response. Additionally, although patients with PCNSL who underwent ASCT in CR1 received a uniform induction regimen, the patients with refractory or relapsed PCNSL and SCNSL/CNS received heterogeneous induction and salvage therapies (<xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>), making definitive conclusions on the efficacy of HDC/ASCT in this cohort of patients difficult. Finally, toxicity evaluation was not performed using the Common Terminology for Adverse Events or objective scoring systems, and toxicity was arbitrarily defined using medical record review. Also, the long-term neurotoxic effects and minimal residual disease status were not evaluated.</p><p id="p0145">Several randomized clinical trials have been investigating the role of HDC/ASCT consolidation therapy compared with WBRT<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref>
<sup>,</sup>
<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref> and nonmyeloablative chemotherapy.<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref>
<sup>,</sup>
<xref rid="bib49" ref-type="bibr"><sup>49</sup></xref> In the PRECIS trial,<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> which included only patients aged&#x000a0;&#x02264; 60 years, those patients randomized to HDC/ASCT with TBC conditioning after induction chemotherapy (n&#x000a0;= 70) had a 2-year PFS of 87% (95% CI, 77%-98%) compared with 63% (95% CI, 49%-81%) for those receiving WBRT (n&#x000a0;= 70). However, the OS after 4 years was similar in both arms (66% vs. 64%). The TRM rate was greater in the HDC/ASCT group (5 deaths vs. 1 death in the WBRT group). Cognitive impairment was documented after WBRT; however, the cognitive function improved or remained stable after HDC/ASCT.<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref> The IELSG32 trial compared WBRT (n&#x000a0;= 55 patients) versus ASCT (n&#x000a0;= 58 patients) with carmustine/thiotepa conditioning for consolidation and showed similar 2-year PFS (76% after WBRT vs. 75% after ASCT; <italic>P</italic>&#x000a0;= .62) and 2-year OS (82% after WBRT vs. 77% after ASCT; <italic>P</italic>&#x000a0;= .91).<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref> The TRM rate was 3% in the ASCT group, with a nonsignificant trend toward impaired attention and executive function 2 years after therapy for those given WBRT.<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref> For nonmyeloablative chemotherapy, 2 trials are in process. The CALGB (Cancer and Leukemia Group B) 51101 trial will compare dose-intensive etoposide and cytarabine chemotherapy with HDC/ASCT using carmustine and thiotepa conditioning,<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref>
<sup>,</sup>
<xref rid="bib49" ref-type="bibr"><sup>49</sup></xref> and the European MATRix/IELSG43 will compare consolidation chemotherapy, consisting of R-DeVIC (rituximab, dexamethasone, etoposide, ifosfamide, carboplatin) with HDC/ASCT using thiotepa and carmustine conditioning.<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref> Data are also available on the use of novel agents targeting components of the B-cell receptor pathway (ie, the Bruton tyrosine kinase inhibitor ibrutinib) and immunomodulatory drugs (eg, lenalidomide and pomalidomide).<xref rid="bib50" ref-type="bibr"><sup>50</sup></xref> These agents have shown promising high response rates but have currently only been tested in the salvage setting.<xref rid="bib51" ref-type="bibr"><sup>51</sup></xref>
</p></sec><sec id="sec5"><title>Conclusion</title><p id="p0150">Overall, our results support the use of HDC/ASCT with CNS-directed conditioning as consolidative therapy for PCNSL with long-term efficacy and manageable side effects. Patients with PCNSL who had undergone ASCT in CR1 appeared to have a survival benefit compared with those patients who had undergone ASCT after CR1. Data for SCNSL and in the relapse setting also appear encouraging. Longer follow-up and comparison with other consolidative therapies will provide further insight and should be reported in the near future.</p><sec id="sec5.1"><title>Clinical Practice Points</title><p id="p0155">
<list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#x02022;</label><p id="p0160">HDC with ASCT has been investigated in patients with PCNSL or NHL with CNS involvement as postremission consolidation or in the relapse setting, with promising results.</p></list-item><list-item id="u0015"><label>&#x02022;</label><p id="p0165">Our study included 48 patients with PCNSL (27 patients) or SCNSL/CNS relapse (21 patients) who had undergone HDC/ASCT with TBC conditioning; of the 27 patients with PCNSL, 21 had undergone ASCT in CR1.</p></list-item><list-item id="u0020"><label>&#x02022;</label><p id="p0170">Overall, our data have shown encouraging long-term efficacy with a 2-year PFS rate of 80.5% (95% CI, 69.9%-92.9%) and a 2-year OS rate of 80.1% (95% CI, 69.2%-92.7%) for all patients.</p></list-item><list-item id="u0025"><label>&#x02022;</label><p id="p0175">The 2-year PFS and OS rate for patients with PCNSL was 84.2% (95% CI, 71.0%-99.8%) and 83.6% (95% CI, 70.1%-99.8%), respectively.</p></list-item><list-item id="u0030"><label>&#x02022;</label><p id="p0180">There appears to be a PFS and OS benefit for patients with PCNSL who undergo transplantation in CR1 compared with those who undergo transplantation beyond CR1 (PFS: HR, 13.36; 95% CI, 1.48-120.18; <italic>P</italic>&#x000a0;= .007; OS: HR, 12.89; 95% CI, 1.43-115.88; <italic>P</italic>&#x000a0;= .008).</p></list-item><list-item id="u0035"><label>&#x02022;</label><p id="p0185">The most common side effects were febrile neutropenia and infection, nausea/vomiting, diarrhea, mucositis, and electrolyte abnormalities, with 4 (8.3%) dying of treatment-related overwhelming infection.</p></list-item><list-item id="u0040"><label>&#x02022;</label><p id="p0190">Reversible neurotoxicity occurred in 27.1% of our patients.</p></list-item><list-item id="u0045"><label>&#x02022;</label><p id="p0195">Our study adds to the increasing data suggesting encouraging disease control and survival for HDC/ASCT with CNS-directed conditioning in PCNSL and secondary CNS NHL.</p></list-item><list-item id="u0050"><label>&#x02022;</label><p id="p0200">Randomized trials are ongoing to compare HDC/ASCT with other consolidative therapies, including WBRT and nonmyeloablative chemotherapy.</p></list-item></list>
</p></sec></sec><sec id="sec6"><title>Disclosure</title><p id="p0205">The authors have stated that they have no conflicts of interest.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Rubenstein</surname><given-names>J.L.</given-names></name><name><surname>Gupta</surname><given-names>N.K.</given-names></name><name><surname>Mannis</surname><given-names>G.N.</given-names></name><name><surname>Lamarre</surname><given-names>A.K.</given-names></name><name><surname>Treseler</surname><given-names>P.</given-names></name></person-group><article-title>How I treat CNS lymphomas</article-title><source>Blood</source><volume>122</volume><year>2013</year><fpage>2318</fpage><lpage>2330</lpage><pub-id pub-id-type="pmid">23963042</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Citterio</surname><given-names>G.</given-names></name><name><surname>Reni</surname><given-names>M.</given-names></name><name><surname>Gatta</surname><given-names>G.</given-names></name><name><surname>Ferreri</surname><given-names>A.J.M.</given-names></name></person-group><article-title>Primary central nervous system lymphoma</article-title><source>Crit Rev Oncol Hematol</source><volume>113</volume><year>2017</year><fpage>97</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">28427529</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Thiel</surname><given-names>E.</given-names></name><name><surname>Korfel</surname><given-names>A.</given-names></name><name><surname>Martus</surname><given-names>P.</given-names></name></person-group><article-title>High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial</article-title><source>Lancet Oncol</source><volume>11</volume><year>2010</year><fpage>1036</fpage><lpage>1047</lpage><pub-id pub-id-type="pmid">20970380</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Korfel</surname><given-names>A.</given-names></name><name><surname>Thiel</surname><given-names>E.</given-names></name><name><surname>Martus</surname><given-names>P.</given-names></name></person-group><article-title>Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma</article-title><source>Neurology</source><volume>84</volume><year>2015</year><fpage>1242</fpage><lpage>1248</lpage><pub-id pub-id-type="pmid">25716362</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Abrey</surname><given-names>L.E.</given-names></name><name><surname>Moskowitz</surname><given-names>C.H.</given-names></name><name><surname>Mason</surname><given-names>W.P.</given-names></name></person-group><article-title>Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis</article-title><source>J&#x000a0;Clin Oncol</source><volume>21</volume><year>2003</year><fpage>4151</fpage><lpage>4156</lpage><pub-id pub-id-type="pmid">14615443</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Colombat</surname><given-names>P.</given-names></name><name><surname>Lemevel</surname><given-names>A.</given-names></name><name><surname>Bertrand</surname><given-names>P.</given-names></name></person-group><article-title>High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group</article-title><source>Bone Marrow Transplant</source><volume>38</volume><year>2006</year><fpage>417</fpage><lpage>420</lpage><pub-id pub-id-type="pmid">16951691</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Illerhaus</surname><given-names>G.</given-names></name><name><surname>Muller</surname><given-names>F.</given-names></name><name><surname>Feuerhake</surname><given-names>F.</given-names></name><name><surname>Schafer</surname><given-names>A.-O.</given-names></name><name><surname>Ostertag</surname><given-names>C.</given-names></name><name><surname>Finke</surname><given-names>J.</given-names></name></person-group><article-title>High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system</article-title><source>Haematologica</source><volume>93</volume><year>2008</year><fpage>147</fpage><lpage>148</lpage><pub-id pub-id-type="pmid">18166803</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Alimohamed</surname><given-names>N.</given-names></name><name><surname>Daly</surname><given-names>A.</given-names></name><name><surname>Owen</surname><given-names>C.</given-names></name><name><surname>Duggan</surname><given-names>P.</given-names></name><name><surname>Stewart</surname><given-names>D.A.</given-names></name></person-group><article-title>Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience</article-title><source>Leuk Lymphoma</source><volume>53</volume><year>2012</year><fpage>862</fpage><lpage>867</lpage><pub-id pub-id-type="pmid">22023529</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Soussain</surname><given-names>C.</given-names></name><name><surname>Suzan</surname><given-names>F.</given-names></name><name><surname>Hoang-Xuan</surname><given-names>K.</given-names></name></person-group><article-title>Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma</article-title><source>J&#x000a0;Clin Oncol</source><volume>19</volume><year>2001</year><fpage>742</fpage><lpage>749</lpage><pub-id pub-id-type="pmid">11157026</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Brevet</surname><given-names>M.</given-names></name><name><surname>Garidi</surname><given-names>R.</given-names></name><name><surname>Gruson</surname><given-names>B.</given-names></name><name><surname>Royer</surname><given-names>B.</given-names></name><name><surname>Vaida</surname><given-names>I.</given-names></name><name><surname>Damaj</surname><given-names>G.</given-names></name></person-group><article-title>First-line autologous stem cell transplantation in primary CNS lymphoma</article-title><source>Eur J Haematol</source><volume>75</volume><year>2005</year><fpage>288</fpage><lpage>292</lpage><pub-id pub-id-type="pmid">16146534</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Montemurro</surname><given-names>M.</given-names></name><name><surname>Kiefer</surname><given-names>T.</given-names></name><name><surname>Schuler</surname><given-names>F.</given-names></name></person-group><article-title>Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study</article-title><source>Ann Oncol</source><volume>18</volume><year>2006</year><fpage>665</fpage><lpage>671</lpage><pub-id pub-id-type="pmid">17185743</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Kiefer</surname><given-names>T.</given-names></name><name><surname>Hirt</surname><given-names>C.</given-names></name><name><surname>Spath</surname><given-names>C.</given-names></name></person-group><article-title>Long-term follow-up of high-dose chemotherapy with autologous stem-cell transplantation and response-adapted whole-brain radiotherapy for newly diagnosed primary CNS lymphoma: results of the multicenter Ostdeutsche Studiengruppe Hamatologie und Onkologie OSHO-53 phase II study</article-title><source>Ann Oncol</source><volume>23</volume><year>2012</year><fpage>1809</fpage><lpage>1812</lpage><pub-id pub-id-type="pmid">22115927</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>T.</given-names></name><name><surname>Forsyth</surname><given-names>P.</given-names></name><name><surname>Chaudhry</surname><given-names>A.</given-names></name></person-group><article-title>High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma</article-title><source>Bone Marrow Transplant</source><volume>31</volume><year>2003</year><fpage>679</fpage><lpage>685</lpage><pub-id pub-id-type="pmid">12692608</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Omuro</surname><given-names>A.</given-names></name><name><surname>Correa</surname><given-names>D.D.</given-names></name><name><surname>DeAngelis</surname><given-names>L.M.</given-names></name></person-group><article-title>R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma</article-title><source>Blood</source><volume>125</volume><year>2015</year><fpage>1403</fpage><lpage>1410</lpage><pub-id pub-id-type="pmid">25568347</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.-B.</given-names></name><name><surname>Batchelor</surname><given-names>T.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name></person-group><article-title>Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma</article-title><source>Cancer</source><volume>121</volume><year>2015</year><fpage>226</fpage><lpage>233</lpage><pub-id pub-id-type="pmid">25204639</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Houillier</surname><given-names>C.</given-names></name><name><surname>Taillandier</surname><given-names>L.</given-names></name><name><surname>Lamy</surname><given-names>T.</given-names></name></person-group><article-title>Whole brain radiotherapy (WBRT) versus intensive chemotherapy with haematopoietic stem cell rescue (IC&#x000a0;+ HCR) for primary central nervous system lymphoma (PCNSL) in young patients: an Intergroup Anocef-Goelams randomized phase II trial (PRECIS)</article-title><source>Blood</source><volume>128</volume><year>2016</year><fpage>782</fpage></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>DeFilipp</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>El-Jawahri</surname><given-names>A.</given-names></name></person-group><article-title>High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission</article-title><source>Cancer</source><volume>123</volume><year>2017</year><fpage>3073</fpage><pub-id pub-id-type="pmid">28369839</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Scordo</surname><given-names>M.</given-names></name><name><surname>Bhatt</surname><given-names>V.</given-names></name><name><surname>Hsu</surname><given-names>M.</given-names></name></person-group><article-title>A&#x000a0;comprehensive assessment of toxicities in patients with central nervous system lymphoma undergoing autologous stem cell transplantation using thiotepa, busulfan, and cyclophosphamide conditioning</article-title><source>Biol Blood Marrow Transplant</source><volume>23</volume><year>2017</year><fpage>38</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">27713090</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Soussain</surname><given-names>C.</given-names></name><name><surname>Hoang-Xuan</surname><given-names>K.</given-names></name><name><surname>Taillandier</surname><given-names>L.</given-names></name></person-group><article-title>Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Soci&#x000e9;t&#x000e9; Fran&#x000e7;aise de Greffe de Mo&#x000eb;lle Osseuse-Th&#x000e9;rapie Cellulaire</article-title><source>J&#x000a0;Clin Oncol</source><volume>26</volume><year>2008</year><fpage>2512</fpage><lpage>2518</lpage><pub-id pub-id-type="pmid">18413641</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Soussain</surname><given-names>C.</given-names></name><name><surname>Choquet</surname><given-names>S.</given-names></name><name><surname>Fourme</surname><given-names>E.</given-names></name></person-group><article-title>Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases</article-title><source>Haematologica</source><volume>97</volume><year>2012</year><fpage>1751</fpage><lpage>1756</lpage><pub-id pub-id-type="pmid">22581000</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Illerhaus</surname><given-names>G.</given-names></name><name><surname>Marks</surname><given-names>R.</given-names></name><name><surname>Ihorst</surname><given-names>G.</given-names></name></person-group><article-title>High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma</article-title><source>J&#x000a0;Clin Oncol</source><volume>24</volume><year>2006</year><fpage>3865</fpage><lpage>3870</lpage><pub-id pub-id-type="pmid">16864853</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Kasenda</surname><given-names>B.</given-names></name><name><surname>Schorb</surname><given-names>E.</given-names></name><name><surname>Fritsch</surname><given-names>K.</given-names></name><name><surname>Finke</surname><given-names>J.</given-names></name><name><surname>Illerhaus</surname><given-names>G.</given-names></name></person-group><article-title>Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma&#x02014;a long-term follow-up study</article-title><source>Ann Oncol</source><volume>23</volume><year>2012</year><fpage>2670</fpage><lpage>2675</lpage><pub-id pub-id-type="pmid">22473593</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Bojic</surname><given-names>M.</given-names></name><name><surname>Berghoff</surname><given-names>A.S.</given-names></name><name><surname>Troch</surname><given-names>M.</given-names></name></person-group><article-title>Haematopoietic stem cell transplantation for treatment of primary CNS lymphoma: single-centre experience and literature review</article-title><source>Eur J Haematol</source><volume>95</volume><year>2015</year><fpage>75</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">25546348</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Schorb</surname><given-names>E.</given-names></name><name><surname>Kasenda</surname><given-names>B.</given-names></name><name><surname>Atta</surname><given-names>J.</given-names></name></person-group><article-title>Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation</article-title><source>Haematologica</source><volume>98</volume><year>2013</year><fpage>765</fpage><lpage>770</lpage><pub-id pub-id-type="pmid">23300179</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Ferreri</surname><given-names>A.J.M.</given-names></name><name><surname>Illerhaus</surname><given-names>G.</given-names></name></person-group><article-title>The role of autologous stem cell transplantation in primary central nervous system lymphoma</article-title><source>Blood</source><volume>127</volume><year>2016</year><fpage>1642</fpage><lpage>1649</lpage><pub-id pub-id-type="pmid">26834241</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Illerhaus</surname><given-names>G.</given-names></name><name><surname>Kasenda</surname><given-names>B.</given-names></name><name><surname>Ihorst</surname><given-names>G.</given-names></name></person-group><article-title>High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial</article-title><source>Lancet Haematol</source><volume>3</volume><year>2016</year><fpage>e388</fpage><lpage>e397</lpage><pub-id pub-id-type="pmid">27476790</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Illerhaus</surname><given-names>G.</given-names></name><name><surname>Fritsch</surname><given-names>K.</given-names></name><name><surname>Egerer</surname><given-names>G.</given-names></name></person-group><article-title>Sequential high dose immuno-chemotherapy followed by autologous peripheral blood stem cell transplantation for patients with untreated primary central nervous system lymphoma&#x02014;a multicentre study by the collaborative PCNSL Study Group Freiburg</article-title><source>Blood</source><volume>120</volume><year>2012</year><fpage>302</fpage></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Cote</surname><given-names>G.M.</given-names></name><name><surname>Hochberg</surname><given-names>E.P.</given-names></name><name><surname>Muzikansky</surname><given-names>A.</given-names></name></person-group><article-title>Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma</article-title><source>Biol Blood Marrow Transplant</source><volume>18</volume><year>2012</year><fpage>76</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">21749848</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Welch</surname><given-names>M.R.</given-names></name><name><surname>Sauter</surname><given-names>C.S.</given-names></name><name><surname>Matasar</surname><given-names>M.J.</given-names></name></person-group><article-title>Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide</article-title><source>Leuk Lymphoma</source><volume>56</volume><year>2015</year><fpage>361</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">24745937</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>M.K.</given-names></name><name><surname>Kang</surname><given-names>E.S.</given-names></name><name><surname>Kim</surname><given-names>D.W.</given-names></name></person-group><article-title>Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation</article-title><source>Int J Hematol</source><volume>98</volume><year>2013</year><fpage>346</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">23868695</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Fraser</surname><given-names>E.</given-names></name><name><surname>Gruenberg</surname><given-names>K.</given-names></name><name><surname>Rubenstein</surname><given-names>J.L.</given-names></name></person-group><article-title>New approaches in primary central nervous system lymphoma</article-title><source>Chin Clin Oncol</source><volume>4</volume><year>2015</year><fpage>11</fpage><pub-id pub-id-type="pmid">25841718</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Wiebe</surname><given-names>V.J.</given-names></name><name><surname>Smith</surname><given-names>B.R.</given-names></name><name><surname>DeGregorio</surname><given-names>M.W.</given-names></name><name><surname>Rappeport</surname><given-names>J.M.</given-names></name></person-group><article-title>Pharmacology of agents used in bone marrow transplant conditioning regimens</article-title><source>Crit Rev Oncol Hematol</source><volume>13</volume><year>1992</year><fpage>241</fpage><lpage>270</lpage><pub-id pub-id-type="pmid">1476655</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Muldoon</surname><given-names>L.L.</given-names></name><name><surname>Soussain</surname><given-names>C.</given-names></name><name><surname>Jahnke</surname><given-names>K.</given-names></name></person-group><article-title>Chemotherapy delivery issues in central nervous system malignancy: a reality check</article-title><source>J&#x000a0;Clin Oncol</source><volume>25</volume><year>2007</year><fpage>2295</fpage><lpage>2305</lpage><pub-id pub-id-type="pmid">17538176</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Gulati</surname><given-names>S.</given-names></name><name><surname>Yahalom</surname><given-names>J.</given-names></name><name><surname>Acaba</surname><given-names>L.</given-names></name></person-group><article-title>Treatment of patients with relapsed and resistant non-Hodgkin&#x02019;s lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation</article-title><source>J&#x000a0;Clin Oncol</source><volume>10</volume><year>1992</year><fpage>936</fpage><lpage>941</lpage><pub-id pub-id-type="pmid">1588372</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Rapoport</surname><given-names>A.P.</given-names></name><name><surname>Rowe</surname><given-names>J.M.</given-names></name><name><surname>Kouides</surname><given-names>P.A.</given-names></name></person-group><article-title>One hundred autotransplants for relapsed or refractory Hodgkin&#x02019;s disease and lymphoma: value of pretransplant disease status for predicting outcome</article-title><source>J&#x000a0;Clin Oncol</source><volume>11</volume><year>1993</year><fpage>2351</fpage><lpage>2361</lpage><pub-id pub-id-type="pmid">8246024</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Qualls</surname><given-names>D.</given-names></name><name><surname>Sullivan</surname><given-names>A.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name></person-group><article-title>High-dose thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation as upfront consolidation for systemic non-Hodgkin lymphoma with synchronous central nervous system involvement</article-title><source>Clin Lymph Myeloma Leuk</source><volume>17</volume><year>2017</year><fpage>884</fpage><lpage>888</lpage></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Herr</surname><given-names>M.M.</given-names></name><name><surname>Barr</surname><given-names>P.M.</given-names></name><name><surname>Rich</surname><given-names>D.Q.</given-names></name><name><surname>Mohile</surname><given-names>N.</given-names></name></person-group><article-title>Clinical features, treatment, and survival of secondary central nervous system lymphoma</article-title><source>Blood</source><volume>124</volume><year>2014</year><fpage>5389</fpage></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Maziarz</surname><given-names>R.T.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>M.-J.</given-names></name></person-group><article-title>Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement</article-title><source>Br J Haematol</source><volume>162</volume><year>2013</year><fpage>648</fpage><lpage>656</lpage><pub-id pub-id-type="pmid">23829536</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Alvarnas</surname><given-names>J.C.</given-names></name><name><surname>Negrin</surname><given-names>R.S.</given-names></name><name><surname>Horning</surname><given-names>S.J.</given-names></name></person-group><article-title>High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin&#x02019;s lymphoma</article-title><source>Biol Blood Marrow Transplant</source><volume>6</volume><year>2000</year><fpage>352</fpage><lpage>358</lpage><pub-id pub-id-type="pmid">10905773</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>van Besien</surname><given-names>K.</given-names></name><name><surname>Przepiorka</surname><given-names>D.</given-names></name><name><surname>Mehra</surname><given-names>R.</given-names></name></person-group><article-title>Impact of preexisting CNS involvement on the outcome of bone marrow transplantation in adult hematologic malignancies</article-title><source>J&#x000a0;Clin Oncol</source><volume>14</volume><year>1996</year><fpage>3036</fpage><lpage>3042</lpage><pub-id pub-id-type="pmid">8918502</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>C.D.</given-names></name><name><surname>Pearce</surname><given-names>R.</given-names></name><name><surname>Taghipour</surname><given-names>G.</given-names></name><name><surname>Green</surname><given-names>E.S.</given-names></name><name><surname>Philip</surname><given-names>T.</given-names></name><name><surname>Goldstone</surname><given-names>A.H.</given-names></name></person-group><article-title>Autologous bone marrow transplantation for patients with non-Hodgkin&#x02019;s lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome&#x02014;a report by the European Bone Marrow Transplant Lymphoma Registry</article-title><source>J&#x000a0;Clin Oncol</source><volume>12</volume><year>1994</year><fpage>2415</fpage><lpage>2422</lpage><pub-id pub-id-type="pmid">7964958</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Kasenda</surname><given-names>B.</given-names></name><name><surname>Ferreri</surname><given-names>A.J.M.</given-names></name><name><surname>Marturano</surname><given-names>E.</given-names></name></person-group><article-title>First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)&#x02014;a systematic review and individual patient data meta-analysis</article-title><source>Ann Oncol</source><volume>26</volume><year>2015</year><fpage>1305</fpage><lpage>1313</lpage><pub-id pub-id-type="pmid">25701456</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Ferreri</surname><given-names>A.J.M.</given-names></name><name><surname>Cwynarski</surname><given-names>K.</given-names></name><name><surname>Pulczynski</surname><given-names>E.</given-names></name></person-group><article-title>Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial</article-title><source>Lancet Haematol</source><volume>4</volume><year>2017</year><fpage>e510</fpage><lpage>e523</lpage><pub-id pub-id-type="pmid">29054815</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>Alnahhas</surname><given-names>I.</given-names></name><name><surname>Jawish</surname><given-names>M.</given-names></name><name><surname>Alsawas</surname><given-names>M.</given-names></name></person-group><article-title>Autologous stem-cell transplantation for primary central nervous system lymphoma: systematic review and meta-analysis</article-title><source>Clin Lymph Myeloma Leuk</source><volume>19</volume><year>2019</year><fpage>e129</fpage><lpage>e141</lpage></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>DeAngelis</surname><given-names>L.M.</given-names></name><name><surname>Seiferheld</surname><given-names>W.</given-names></name><name><surname>Schold</surname><given-names>S.C.</given-names></name><name><surname>Fisher</surname><given-names>B.</given-names></name><name><surname>Schultz</surname><given-names>C.J.</given-names></name><collab>Radiation Therapy Oncology Group</collab></person-group><article-title>Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group study 93-10</article-title><source>J&#x000a0;Clin Oncol</source><volume>20</volume><year>2002</year><fpage>4643</fpage><lpage>4648</lpage><pub-id pub-id-type="pmid">12488408</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Omuro</surname><given-names>A.M.P.</given-names></name><name><surname>Ben-Porat</surname><given-names>L.S.</given-names></name><name><surname>Panageas</surname><given-names>K.S.</given-names></name></person-group><article-title>Delayed neurotoxicity in primary central nervous system lymphoma</article-title><source>Arch Neurol</source><volume>62</volume><year>2005</year><fpage>1595</fpage><lpage>1600</lpage><pub-id pub-id-type="pmid">16216945</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Ferreri</surname><given-names>A.J.M.</given-names></name><name><surname>Cwynarski</surname><given-names>K.</given-names></name><name><surname>Pulczynski</surname><given-names>E.J.</given-names></name></person-group><article-title>Effects on survival and neurocognitive functions of whole-brain radiotherapy (WBRT) and autologous stem cell transplantation (ASCT) as consolidation options after high-dose methotrexate-based chemoimmunotherapy in patients with newly diagnosed primary CNS lymphoma (PCNSL): results of the second randomization of the IELSG32 trial</article-title><source>Blood</source><volume>128</volume><year>2016</year><fpage>511</fpage></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name><surname>Houillier</surname><given-names>C.</given-names></name><name><surname>Taillandier</surname><given-names>L.</given-names></name><name><surname>Dureau</surname><given-names>S.</given-names></name></person-group><article-title>Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the Intergroup ANOCEF-GOELAMS randomized phase II PRECIS study</article-title><source>J&#x000a0;Clin Oncol</source><volume>37</volume><year>2019</year><fpage>823</fpage><lpage>833</lpage><pub-id pub-id-type="pmid">30785830</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name><surname>Rubenstein</surname><given-names>J.L.</given-names></name><name><surname>Hsi</surname><given-names>E.D.</given-names></name><name><surname>Johnson</surname><given-names>J.L.</given-names></name></person-group><article-title>Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)</article-title><source>J&#x000a0;Clin Oncol</source><volume>31</volume><year>2013</year><fpage>3061</fpage><lpage>3068</lpage><pub-id pub-id-type="pmid">23569323</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name><surname>Grommes</surname><given-names>C.</given-names></name><name><surname>Nayak</surname><given-names>L.</given-names></name><name><surname>Tun</surname><given-names>H.W.</given-names></name><name><surname>Batchelor</surname><given-names>T.T.</given-names></name></person-group><article-title>Introduction of novel agents in the treatment of primary CNS lymphoma</article-title><source>Neuro Oncol</source><volume>21</volume><year>2019</year><fpage>306</fpage><lpage>313</lpage><pub-id pub-id-type="pmid">30423172</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name><surname>Mendez</surname><given-names>J.S.</given-names></name><name><surname>Grommes</surname><given-names>C.</given-names></name></person-group><article-title>Treatment of primary central nervous system lymphoma: from chemotherapy to small molecules</article-title><source>Am Soc Clin Oncol Educ Book</source><volume>38</volume><year>2018</year><fpage>604</fpage><lpage>615</lpage><pub-id pub-id-type="pmid">30231317</pub-id></element-citation></ref></ref-list><fn-group><fn id="d32e2060"><p id="ntpara0010">H.A.E. and J.T. share senior authorship.</p></fn></fn-group></back></article>